| scholarly article | Q13442814 |
| P50 | author | Ahmed El-Shamy | Q38324019 |
| P2093 | author name string | Hak Hotta | |
| Motoko Nagano-Fujii | |||
| Susumu Imoto | |||
| Noriko Sasase | |||
| Soo-Ryang Kim | |||
| P2860 | cites work | Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera | Q43037304 |
| Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection | Q43038296 | ||
| Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site | Q43038313 | ||
| Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication | Q43038550 | ||
| Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy | Q43048004 | ||
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. | Q50578652 | ||
| Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients | Q80170461 | ||
| Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein | Q24319002 | ||
| Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy | Q27469310 | ||
| Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses | Q27472905 | ||
| Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy | Q27477674 | ||
| Viral Determinants of Resistance to Treatment in Patients with Hepatitis C | Q27478062 | ||
| Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region | Q27478292 | ||
| Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis | Q27860811 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources | Q29620774 | ||
| Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a | Q30757296 | ||
| Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy | Q34099523 | ||
| Predictors of response to therapy for chronic hepatitis C. | Q35877904 | ||
| Therapy of hepatitis C: from empiricism to eradication | Q36382235 | ||
| Peginterferon and ribavirin for chronic hepatitis C. | Q36675912 | ||
| Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy | Q42986366 | ||
| Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. | Q42988613 | ||
| Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance | Q42990051 | ||
| Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. | Q42991459 | ||
| Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients | Q42994490 | ||
| Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy | Q42999651 | ||
| Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. | Q43034678 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| ribavirin | Q421862 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 38-47 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy | |
| P478 | volume | 48 |
| Q39428400 | A point mutation at Asn-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis C virus markedly enhances the sensitivity to antibody neutralization |
| Q38552131 | APASL consensus statements and management algorithms for hepatitis C virus infection. |
| Q37401160 | Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response. |
| Q43034369 | Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment |
| Q50555852 | Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. |
| Q42998703 | Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. |
| Q42994827 | Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. |
| Q42694877 | Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin |
| Q34026121 | Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy |
| Q45367431 | Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy |
| Q82156533 | Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C |
| Q43047642 | Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b. |
| Q43038499 | Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy |
| Q45357130 | Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment |
| Q45362210 | Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients |
| Q36349997 | Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching |
| Q42980276 | Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection |
| Q43000694 | Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. |
| Q42232746 | Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection |
| Q35641185 | Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus |
| Q42980375 | Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. |
| Q43047749 | Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy |
| Q42991231 | Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. |
| Q34075689 | Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. |
| Q34342092 | Evolution of interferon-based therapy for chronic hepatitis C. |
| Q58701375 | Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome |
| Q26825715 | Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C |
| Q43033327 | Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. |
| Q34485877 | Future research and collaboration: the "SINERGIE" project on HCV (South Italian Network for Rational Guidelines and International Epidemiology). |
| Q28540849 | Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems |
| Q30402699 | Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time |
| Q45353010 | Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology |
| Q35008521 | HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin |
| Q26775815 | Hepatitis C genotype 4: The past, present, and future |
| Q42989949 | Hepatitis C virus 1b viral factors (core, NS3, and NS5A) and increased risk of hepatocellular carcinoma |
| Q34411617 | Hepatitis C virus NS5A inhibitors and drug resistance mutations |
| Q24628717 | Hepatitis C virus protease inhibitor-resistance mutations: our experience and review |
| Q37772959 | Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. |
| Q43000460 | High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected wi |
| Q36676315 | High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment |
| Q36541206 | IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients |
| Q42603731 | Identification and characterization of a natural inter-genotypic (2b/1b) recombinant hepatitis C virus in Japan |
| Q38224436 | Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview |
| Q37230981 | Impact of host and virus genome variability on HCV replication and response to interferon |
| Q31156692 | Incidence of HCV induced-Esophageal varices in Egypt: Valuable knowledge using data mining analysis |
| Q42223317 | Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant |
| Q43038424 | Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. |
| Q42996032 | Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy |
| Q36414090 | NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients |
| Q40375437 | New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. |
| Q34182392 | Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment |
| Q43428258 | Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B. |
| Q43034121 | Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy |
| Q42987712 | Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma |
| Q35614537 | Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a. |
| Q42978648 | Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load |
| Q37125066 | Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. |
| Q42988539 | Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study |
| Q34625761 | Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation |
| Q42978115 | Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients |
| Q41690587 | Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions |
| Q39157496 | Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. |
| Q50552503 | Response-guided peginterferon-alpha-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. |
| Q38121422 | Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. |
| Q42997927 | Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. |
| Q34154593 | Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy |
| Q43034814 | Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy |
| Q30356602 | Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population. |
| Q36270505 | Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein |
| Q37966703 | Tailor-made therapy for viral hepatitis: recent advances |
| Q43224173 | The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. |
| Q41294797 | The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay |
| Q55212538 | The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. |
| Q33905948 | The mode and tempo of hepatitis C virus evolution within and among hosts |
| Q38668968 | The role of HCV proteins on treatment outcomes |
| Q37546699 | Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection |
| Q37597927 | Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. |
Search more.